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Abstract
Pancreatic ductal adenocarcinoma is the most common and aggressive type of pancreatic cancer, with a 5-year survival
rate that is less than 10%. New biomarkers to aid in predicting the prognosis of pancreatic ductal adenocarcinoma
patients are needed. Previous proteomic studies have to a great extent focused on finding proteins of value for the diag-
nosis of pancreatic ductal adenocarcinoma. There is a lack of studies that have profiled the serum or plasma proteome
in order to discover candidates for new prognostic biomarkers. In this study, we have used ultra-performance liquid
chromatography–ultra-definition mass spectrometry to analyze the serum samples of 21 pancreatic ductal adenocarci-
noma patients with short or long survival. Statistical analysis discovered 31 proteins whose expression differed signifi-
cantly between pancreatic ductal adenocarcinoma patients with short or long survival. Pathway analysis discovered
multiple canonical pathways enriched in this data set, with several pathways having roles in inflammation and lipid meta-
bolism. The serum proteins identified here, which include complement components and several enzymes, could be of
value as candidates for new noninvasive prognostic markers.
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Introduction
Pancreatic cancer comprises several distinct neoplasms
arising from the pancreas and is the seventh most com-
mon cause of cancer death worldwide. Pancreatic duc-
tal adenocarcinoma (PDAC) accounts for around 85%
of all pancreatic cancer cases and is the most aggressive
type of pancreatic cancer, with a very poor prognosis
and most patients presenting with metastatic disease.
Each year, around 330,000 new cases of PDAC are
diagnosed worldwide, with an almost equal number of
deaths.1 The 5-year survival rate for pancreatic cancer
patients is under 10%. The only possible way to cure
PDAC is through surgery, although less than 20% of
patients present with potentially resectable tumors. For
these patients, the 5-year survival is only increased to
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20%, which leads to treatment for most patients being
focused on palliative care.2,3
Prognosis remains poor even for patients who
undergo radical surgery, with patients being faced with
significant morbidity, and up to 80% of patients
develop recurrence.4,5 PDAC presents with nonspecific
symptoms, such as weight loss and abdominal pain,
making it difficult to diagnose. Patients are often
elderly and in poor overall health, and PDAC is also
associated with multiple comorbidities, which further
complicate treatment.6 New biomarkers to aid in the
prediction of prognosis, treatment response, and
follow-up of PDAC are needed, as carbohydrate anti-
gen 19-9 (CA 19-9) is the only routinely used serum-
based biomarker for PDAC.7 CA19-9 is an indepen-
dent prognostic variable and high levels of CA19-9 are
correlated with decreased survival in PDAC patients.
However, as CA19-9 levels can also be elevated due to
other benign and malignant conditions, caution must
be used when interpreting results.8,9
Mass spectrometry is often used to analyze the pro-
teome for potential biomarker candidates. Proteins
detectable in serum can be measured from easily
obtained blood samples and are therefore ideal as bio-
markers.10 A peptide panel that would be cost-effective,
able to detect early disease, and able to be run even
when symptoms are general and non-specific would be
ideal. Mass spectrometry–based proteomic analysis of
serum gives information about the expression levels
of hundreds of proteins simultaneously in a single
experiment, and the results can be further analyzed to
obtain candidates for diagnostic and prognostic use.
Furthermore, information about dysregulated path-
ways in the disease can also be obtained, and this
information can be used to design studies to gain
mechanistic insights into disease progression and thera-
peutic target discovery.
Previous studies aiming to identify biomarkers for
PDAC patients have to a large extent focused on find-
ing proteins of use in the diagnosis of PDAC and have
investigated the differences in protein expression
between serum from PDAC patients and healthy con-
trols or between PDAC tissue and healthy pancreatic
tissue.11–17 Several studies have investigated if specific
proteins are linked with prognosis and survival in
PDAC patients, although these have mainly utilized tis-
sue samples. A study by Winter et al. hypothesized that
tumor biology was the main driver of survival groups
separated by a minimum of 1.5 years between short-
and long-term survival. The authors used tissue micro-
arrays comprised of tumor samples associated with
short- and long-term survival after PDAC resection.
They subsequently discovered that the proteins,
mesothelin (MSLN) and mucin-1 (MUC1) (which has
previously been identified as a protein carrier of the
CA 19-9 antigen) were predictors of early cancer-
specific mortality.18,19 Few studies have analyzed serum
samples from PDAC patients in order to find proteins
linked to survival and prognosis. One study analyzed
levels of Dickkopf-1 (DKK1) in the serum of PDAC
patients by enzyme-linked immunosorbent assay
(ELISA) and found that DKK1 levels increased with
increasing tumor stage. DKK1 expression in tissues
correlated with its expression in serum and patient sur-
vival was lower in patients with higher DKK1 levels.20
Another study using 2D electrophoresis found that
serum levels of cofilin-1 increased with PDAC progres-
sion, indicating that cofilin-1 could be a potential prog-
nostic marker of PDAC.21
Prognostic markers for PDAC could help to predict
patients’ prognosis and subsequently guide treatment
decisions. By identifying those patients with a poor
prognosis, patients could be selected for more aggres-
sive treatment. Biomarkers associated with poor prog-
nosis also offer the potential to become targets for new
therapies.22 In this pilot study, we have analyzed the
serum proteome of a small cohort of PDAC patients by
mass spectrometry and compared the protein expres-
sion between patients with short- and long-term sur-
vival, in order to discover proteins that could be of
value as new candidates for prognostic biomarkers. We
discovered multiple proteins whose expression differed
significantly between the groups, which after further
studies and validation could be of clinical utility.
Materials and methods
Patient samples
This study included preoperative serum samples from
22 patients with PDAC who underwent pancreatico-
duodenal resection at the Department of Surgery,
Helsinki University Hospital, between 2001 and 2011.
Bilirubin levels were measured preoperatively and all
jaundiced patients underwent an endoscopic procedure
and received a biliary stent prior to operation. At the
time when the serum samples for this study were col-
lected, the bilirubin levels of all patients had normal-
ized (data not shown). Of the patients in this study, 12
patients were male and 10 were female, and their age
ranged from 54 to 79. The patients were chosen accord-
ing to their postoperative survival, with 11 patients
dying within 1 year after surgery (short-term survival)
and 11 patients surviving at least 5 years after surgery
(long-term survival). Detailed patient characteristics
including tumor stage, grade, location, and patient age,
adjuvant therapy status, survival, and cause of death
are given in Supplementary Table 1. Serum samples
were stored at 280C until further processed as
described below. This study was approved by the
Surgical Ethics Committee of Helsinki University
Hospital (Dnro HUS 226/E6/06, extension TMK02 §66
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17.4.2013) and was carried out in accordance with the
Declaration of Helsinki. Written informed consent was
obtained from all patients included in this study.
Sample processing and digestion
The serum samples were processed as previously
described.23,24 Briefly, the samples were thawed before
top 12 protein depletion was performed using the
TOP12 protein depletion kit (Pierce, ThermoFisher,
MA, USA) according to the manufacturer’s instruc-
tions. The total protein concentration was determined
in the depleted serum using the Pierce BCA assay kit
(Pierce, ThermoFisher, MA, USA). The amount of
serum equivalent to 100mg protein was aliquoted and
dried, after which it was dissolved in Tris buffer con-
taining urea. Dithiothreitol (DTT) was added to the
samples, which were shaken for 1 h, after which iodoa-
cetamide was added. Samples were shaken another
hour at room temperature, after which additional DTT
was added and the samples were shaken again and then
diluted using mQ. Trypsin was added at a ratio of 1:50
trypsin to protein. Digestion was carried out at 37C
overnight, and the next day 30mg of tryptic peptides
were cleaned and dissolved in 0.1% formic acid with
12.5 fmol/mL of Hi3 spike-in standard peptides (Waters,
MA, USA).
Ultra-performance liquid chromatography–ultra-
definition mass spectrometry and quantification
UPLC–UDMSE. Ultra-performance liquid chromatogra-
phy–ultra-definition mass spectrometry (UPLC–
UDMSE) was performed as previously described.23,24
In summary, 4mL of each sample (around 1.4mg pro-
tein) was injected into a nanoACQUITY UPLC system
(Waters Corporation, MA, USA). TRIZAIC nanoTile
85mm 3 100mm HSS-T3u wTRAP was used for
separation. Data were acquired in data-independent
acquisition fashion using UDMSE mode with a Synapt
G2S HDMS (Waters Corporation, MA, USA). Data
were collected in the range of 100–2000m/z, scan time
of 1 s, ion-mobility spectrometry (IMS) wave velocity
of 650m/s, and collision energy was ramped from 20 to
60V. Calibration was performed using Glu1-
Fibrinopeptide B MS2 fragments. Glu1-Fibrinopeptide
B precursor ions were used as a lock mass during the
runs. All samples were run in triplicates.
Data analysis. Data analysis and label-free quantifica-
tion were performed as previously described.23–26
Progenesis QI for proteomics automatically performs
match-between-runs (aligning results from different
runs), which results in increased reliability and reprodu-
cibility. The parsimony principle was used to group the
proteins, and peptides unique to the protein were also
reported, meaning that the protein hits were reported
as the minimum set that comprises all observed pep-
tides. Due to over-stringency, Progenesis QI for proteo-
mics does not follow a strict parsimonious approach.27
If two proteins are found with common peptides, the
protein with fewer peptides is subsumed into the pro-
tein with more peptides. Relevant proteins are listed as
a group under the lead protein, which is the one with
the highest coverage or score. Quantitation is performed
with the lead identity peptide data. For more details, see
Nonlinear Dynamics’ website (www.nonlinear.com).
The mass spectrometry proteomics data generated in
this project have been deposited to the Proteome
Xchange Consortium via the PRIDE28,29 partner repo-
sitory with the data set identifier PXD005144.
Further analysis. The differences between the two groups
(short and long survival) were analyzed using the
Mann–Whitney U test. Principal component analysis
(PCA) was performed using Progenesis QI for proteo-
mics. Data were normalized by Pareto scaling and hier-
archical clustering was performed using the program
MetaboAnalyst, version 4.0.30,31 For generating the
heatmap, the following parameters were used: distance
measure: Pearson, clustering algorithm: Ward, and
‘‘autoscale features.’’ Pathway analysis was performed
using ingenuity pathway analysis (IPA) (QIAGEN
Bioinformatics, Redwood City, CA, USA). Only those
proteins with a p-value of \0.05 were used for path-
way analysis. Receiver operating characteristic (ROC)
curves were obtained using SPSS version 25.0 (IBM
SPSS Statistics, IBM Corporation, Armonk, NY), and
the results are reported as area under the ROC curve
(AUROC) values.
Results
Protein identification
In this study, we analyzed serum samples from a total
of 21 PDAC patients (after the exclusion of one sample
that did not normalize, marked in Supplementary Table
1). The samples were divided into groups depending on
patient survival, short (n=10) or long (n=11). A total
of 140 proteins with two or more unique peptides were
quantified. The full list of proteins with relevant data is
given in Supplementary Table 2. Proteins with p-values
greater than 0.05 were not considered to be significantly
different between the two groups.
Differentially expressed proteins
A total of 31 proteins passed the requirement of having
a p-value of less than 0.05 when analyzed by the Mann–
Whitney U test (Table 1) and their expression was
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therefore determined to be significantly different between
the two groups. These proteins are given with the normal-
ized abundance per sample in Supplementary Table S3.
Of these proteins, 20 had higher levels in patients with
long survival, and 11 proteins had higher levels in
patients with short survival. The protein with the largest
fold change (10.6) was CD5 antigen-like (CD5L), which
displayed higher levels in patients with long survival. The
proteins with the second and third largest fold changes
(5.7 and 3.8, respectively) were keratin, type II cytoskele-
tal 2 epidermal (KRT2), and diphosphomevalonate dec-
arboxylase (MVD). KRT2 had higher levels in patients
with short survival, while MVD had higher levels in
patients with long survival. We also found several pro-
teins with roles in inflammation to have higher levels in
patients with short survival. These included multiple com-
plement components and C-reactive protein (CRP).
PCA and hierarchical clustering
PCA is used to determine the principle axes of abun-
dance variation and is useful in identifying outliers.
The PCA biplot is used to identify and visualize the
relationship between two groups as it captures the dif-
ferences between the groups. Figure 1 shows the PCA
biplot when the samples were divided into groups based
on patient survival and when all 140 proteins with two
or more unique peptides were considered. The R2X of
this PCA biplot was 0.4111.
The samples were also divided into three groups based
on the years they were collected (2001–2004, 2006–2008,
and 2010–2011) in order to investigate if protein expres-
sion could be affected by the time the samples were
stored in the freezer. As seen in Supplementary Figure 1,
the PCA biplot when all 140 proteins with two or more
unique peptides were used shows no separation between
the three groups, confirming that storage time did not
affect protein expression.
The heatmap generated when only the 31 proteins
that passed the cutoff of a Mann–Whitney U test p-
value of less than 0.05 between the two groups is given
in Supplementary Figure 2. The figure shows that sam-
ples from patients with short or long survival form sep-
arate clusters, although several of the samples from
patients with long survival clustered together with those
from patients with short survival.
Pathway analysis
Pathway analysis by IPA found multiple canonical
pathways that were enriched in this data set. The top
five pathways enriched were the complement system,
liver X receptor (LXR)/retinoid X receptor (RXR) acti-
vation, farnesoid X receptor (FXR)/RXR activation,
acute-phase response signaling, and systemic lupus
erythematosus signaling. The significantly different
proteins that are part of these pathways are given in
Supplementary Table 4 with their relevant information.
The full list showing all canonical pathways enriched in
this data set is given in Figure 2. Pathway analysis by
IPA also generated networks of protein–protein inter-
actions, and the top network is shown in Figure 3. This
network was found to be associated with the following
functions: developmental disorder, hereditary disorder,
and immunological disease.
Discussion
In this study, we have used label-free proteomics to
analyze the serum protein profiles of a cohort of PDAC
patients with no apparent clinicopathological reasons
for the differences seen in their survival (short or long).
We discovered a total of 31 serum proteins whose levels
Figure 1. The PCA biplot showing samples from PDAC patients with short and long survival when all 140 proteins with two or
more unique peptides were considered.
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were significantly different between patients with short
or long survival (Table 1) and that could be candidates
for new noninvasive prognostic markers. Patients with
short-term survival can be said to have had a poor
prognosis and patients with long-term survival a good
prognosis, since there were no apparent reasons for the
discrepancies seen in survival. These 31 proteins were
subsequently used for pathway analysis and generation
of protein networks by IPA. Twenty proteins showed
higher levels in patients with short survival, including
all complement proteins except for complement factor
H-related protein 5 (CFHR5), while the remaining 11
proteins showed higher levels in patients with long sur-
vival, associating them with a good prognosis. These
included tetranectin and APOC1, two serum proteins
also detected in our previous study that analyzed serum
samples from colorectal cancer (CRC) patients with
high versus low CRP levels and different survival times.
Similar to this study, higher levels of serum tetranectin
were seen in PDAC patients with long 5-year survival.
However, in PDAC patients, higher levels of APOC1
were seen in patients with long survival, whereas in the
CRC study APOC1 levels were higher in patients with
short survival.32 These 31 proteins are therefore of
interest for further studies investigating if they could be
of future clinical use.
A previous study aiming to discover serum biomar-
kers for pancreatic cancer patients using electrospray
ionization (ESI) MS studied serum samples from
PDAC patients and healthy controls. The authors dis-
covered that three acute-phase proteins, a-2-macroglo-
bulin, ceruloplasmin, and complement C3, were
increased in the serum of PDAC patients.33 We also
identified both ceruloplasmin and complement C3 in
our patient samples, and both had higher levels in the
serum of patients with short survival. This further sup-
ports the use of ceruloplasmin and complement C3 as
Figure 2. Pathway analysis showing the canonical pathways enriched in samples from PDAC patients with short or long survival.
Only proteins that passed the cutoff of a Mann–Whitney p-value of less than 0.05 were used for pathway analysis.
Figure 3. Pathway analysis showing the top network of
protein–protein interactions in samples from PDAC patients
with short or long survival. Proteins in red are proteins that
were identified in our study and which displayed higher levels in
patients with short survival. Proteins in green are proteins that
displayed lower levels in patients with short survival. Proteins in
white are proteins that, although not identified in our study, play
roles in this network and interact with the proteins identified.
Only proteins that passed the cutoff of a Mann–Whitney p-value
of less than 0.05 were used for pathway analysis.
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possible diagnostic and prognostic markers for PDAC.
Levels of ceruloplasmin, a protein that transports
serum copper, have previously been found to be signifi-
cantly elevated in the serum of patients with various
disseminated solid malignant tumors including lung,
breast, head and neck, and gastrointestinal cancers.34
Both ceruloplasmin and complement C3, as well as
multiple other proteins detected in our study, including
CRP and complement components, are acute-phase
proteins whose concentrations change during inflam-
mation.35 As mentioned earlier, previous proteomic
studies of PDAC have mainly focused on finding pro-
teins of value for the diagnosis of PDAC. There is a
paucity of studies that have profiled the serum or
plasma proteome in order to discover candidates for
new prognostic biomarkers.
Cancer has been linked to inflammation for many
decades based on observations that tumors often arose
at sites of chronic inflammation and the presence of
inflammatory cells in biopsies. The inflammatory
tumor microenvironment directly contributes to neo-
plastic progression, and tumor cells also co-opt signal-
ing molecules of the innate immune system for their
own use.36,37 PDAC has been recognized as an
inflammation-driven cancer, with inflammation consti-
tuting a critical component of PDAC initiation and
progression. The importance of inflammation is further
supported by the fact that conditions such as chronic
pancreatitis, which is characterized by chronic inflam-
mation, significantly increases the risk of developing
PDAC.38,39 The complement cascade contributes to
both acute and chronic inflammation and has mostly
been considered an effector of innate immunity. Since
it is an important component of the inflammatory
response and inflammation is involved in tumorigenesis
and cancer progression, activation of the complement
system in the tumor microenvironment contributes to
pro-tumor processes. It has been shown to facilitate
various aspects of cancer, including sustained prolifera-
tion, angiogenesis, invasion, and metastasis.40,41 A
recent study by Law et al.42 used quantitative proteo-
mics to analyze PDAC liver metastases and identified
four distinct PDAC microenvironment subtypes,
including an inflammatory subtype that did not
respond to FOLFIRINOX treatment. This subtype
was enriched for proteins related to complement activa-
tion and adaptive immune response, among others.
The results from their study and our current study indi-
cate that it would be of interest to identify a panel of
serum and/or tumor tissue proteins that could be routi-
nely used to classify inflammatory tumors, as well as
other PDAC subtypes, as patients with these tumors
may benefit from a more aggressive treatment regimen
not including FOLFIRINOX. As we also identified
multiple complement components whose levels were
higher in PDAC patients with short survival (Table 1),
this further indicates that patients with inflammatory
tumors have a very poor prognosis.
In our study, we also discovered that levels of CRP
were higher in patients with short survival compared to
those with long survival (Table 1). Elevated levels of
CRP, an acute-phase protein, have previously been
linked with poor prognosis in pancreatic cancer
patients. In one study, the median survival of patients
with an acute-phase response (CRP. 10mg/L) was
66 days, while the median survival for patients without
an acute-phase response was 222days. The acute-phase
response is also associated with metabolic disturbances,
something that could account for the dysregulated lev-
els of certain proteins involved in metabolism, such as
several apolipoproteins, which were also seen in our
study.43,44 We observed differences in serum levels of
proteins such as CRP and other acute-phase proteins
between PDAC patients with short and long survival,
but levels of these proteins increase and decrease in
general during inflammation. Elevated serum levels can
therefore also be seen in the serum of patients with
other diseases, meaning that these proteins are nonspe-
cific for PDAC. While they could be used as prognostic
markers for patients already diagnosed with PDAC,
they most likely would not be helpful in the diagnosis
of PDAC. However, we have previously shown that
elevated levels of CRP predict worse survival in
patients with resectable PDAC.45 As CRP was found
to have significantly higher levels in patients with short
survival in our current study, this finding validates our
results by indicating that we have accurately identified
proteins whose levels differ between patients with
short- and long-term survival.
Pathway analysis by IPA also revealed canonical
pathways that were enriched in our data set. The top
pathways were several involved in inflammation, such
as the complement system and acute-phase response
signaling (discussed above), as well as LXR/RXR and
FXR/RXR activation, which are involved in metabo-
lism. LXRs are nuclear receptors that function as cho-
lesterol sensors, while FXRs are nuclear bile acid
receptors. Both form heterodimers with RXRs and
play important roles in regulating various aspects of
metabolism. LXRs have also been established as modu-
lators of not only lipid metabolism but also inflamma-
tion and immunity.46,47 Metabolic reprogramming and
dysfunctional lipid metabolism are known to occur in
cancer, which may explain the dysregulation of LXR/
FXR and RXR/FXR activation seen in these PDAC
patients.48
One strength of this study is that the patients were
carefully chosen and the only substantial difference
between the patients in this study was in survival. In
addition, the PCA biplot given in Supplementary
Figure 1 confirms that the differences in protein expres-
sion seen between the short and long survival group are
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actually due to the primary variable studied (survival
time) and were not affected by factors such as time in
storage. This study was limited by the fact that it did
not include any samples from patients with inflamma-
tion due to other causes, such as pancreatitis, which
could have helped remove inflammation-related pro-
teins nonspecific for PDAC. If these had been removed,
it may have been possible to discover proteins specific
for PDAC that were present in low concentrations. We
have, however, previously compared the proteome
between patients with chronic pancreatitis and PDAC.
Similar to here, levels of inflammation-related proteins
were found to differ between the serum of these
patients, and similar pathways were enriched in this
data set as in our current study.23 Our current study
was limited by the small cohort of PDAC patients it
utilized, due to the costly and tedious nature of sample
preparation and analysis. While it identifies several
possible candidates for prognostic markers, this is only
the initial step, as candidate proteins would have to be
validated in a larger cohort of patients before being of
clinical use.49 One way to do this is through the use of
ELISAs, as ELISAs for many of the identified proteins
are available. A validation project using ELISAs and
aiming to analyze the top candidate proteins, including
CD5L, MVD, CFHR5, and CRP as a control in a
larger cohort of PDAC patients is currently underway.
In this pilot study, we identified 31 serum proteins
whose levels differed significantly between samples
from PDAC patients with short or long survival. These
proteins displayed good AUROC values and could
therefore be of value as prognostic markers for patients
already diagnosed with PDAC. These types of prognos-
tic markers could help to give more accurate prognostic
information and subsequently aid in treatment deci-
sions. By predicting the prognosis of PDAC patients, it
would be possible to identify patients with good or
poor prognosis. Patients tentatively predicted to have a
good prognosis may be able to be treated with less
aggressive chemotherapy regimens, which would spare
them from undergoing unnecessarily harsh treatment,
although the overall prognosis of PDAC is still poor.
For the group of patients predicted to have a poor
prognosis, more aggressive therapies may be needed if
their general health allows it. Depending on the situa-
tion and outlook, patients predicted to have a poor
prognosis may potentially benefit more from palliative
care than radical surgery and aggressive treatment, as
recovery time is often long after surgery. The findings
of this pilot study therefore may help to improve the
treatment and care of PDAC patients, although further
validation of the proteins identified here is still needed.
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